Theravance Biopharma, Inc. $TBPH Stock Holdings Lessened by Oasis Management Co Ltd.

Oasis Management Co Ltd. reduced its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 35.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 727,161 shares of the biopharmaceutical company’s stock after selling 391,774 shares during the quarter. Theravance Biopharma comprises approximately 0.9% of Oasis Management Co Ltd.’s portfolio, making the stock its 10th biggest holding. Oasis Management Co Ltd.’s holdings in Theravance Biopharma were worth $13,605,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TBPH. HRT Financial LP increased its stake in Theravance Biopharma by 892.8% in the fourth quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after purchasing an additional 209,397 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Theravance Biopharma by 12.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after purchasing an additional 92,253 shares during the last quarter. EntryPoint Capital LLC increased its stake in Theravance Biopharma by 14.3% in the fourth quarter. EntryPoint Capital LLC now owns 34,575 shares of the biopharmaceutical company’s stock valued at $647,000 after purchasing an additional 4,320 shares during the last quarter. Integrated Quantitative Investments LLC increased its stake in Theravance Biopharma by 317.7% in the fourth quarter. Integrated Quantitative Investments LLC now owns 105,143 shares of the biopharmaceutical company’s stock valued at $1,967,000 after purchasing an additional 79,971 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Theravance Biopharma by 83.5% in the fourth quarter. New York State Common Retirement Fund now owns 12,310 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 5,600 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on TBPH. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. TD Cowen upped their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, B. Riley Financial upped their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.83.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $16.64 on Friday. The firm has a market capitalization of $857.79 million, a PE ratio of 7.56 and a beta of 0.17. The business has a 50-day moving average of $16.46 and a two-hundred day moving average of $17.47. Theravance Biopharma, Inc. has a 12 month low of $10.42 and a 12 month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post 1.58 earnings per share for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.65% of the stock is owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.